Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation for Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Anti-tumor Activity of WGc-043 Injection in Patients With Advanced Malignant Solid Tumors: Phase I Study

NCT07028047 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT07028047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07028047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation for Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Anti-tumor Activity of WGc-043 Injection in Patients With Advanced Malignant Solid Tumors: Phase I Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 23, 2025
Completion date
June 30, 2028
Enrollment
64 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ebv-positive malignant solid tumors